Biofilm Project

Screens novel biofilm inhibitors, which may be used as adjunctive therapy in antibacterial treatment of resistant chronic gram negative infections.

CopA Project

Works on a novel bacterial target for development of new antibiotics. Based on structural insight into the Bacterial heavy metal pump, CopA, which is essential for bacterial survival, the focus is to develop small molecule inhibitors of the pump.

Cytoguide ApS

Cytoguide is devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages.

Galecto

The Galecto Galectin-3 inhibitors for chemotherapy project develops improved cancer treatment. Galectin-3 is involved in many aspects of cell growth and by targeting Galectin-3 using small molecule inhibitors, the effectiveness of existing anti-cancer agents can be increased.

InVacc

InVacc possesses a proprietary platform for enhancing the potency of DNA-vaccines. The InVacc technology delivers faster, stronger and more long-lived immuneresponses to acute and chronic infections.

Nanovi

Nanovi is raising the standard of cancer radiotherapy by improving the precision of radiation delivery. Nanovi develops x-ray dense nanoparticles to directly mark tumors, resulting in improved radiation therapy. Nanovi’s NanoTrap™ technology fits into current treatment routines and bypasses the surgical procedure required for conventional radiotherapy markers.

NovVac

NovVac has developed a unique bioinformatics platform for identifying pathogen B-cell antigens with high immunoprotective potential. Screening by VacFinder™ is performed at the whole-genome level and validated antigens are vaccine candidates.

Pcovery ApS

Pcovery, Inc. is focusing on structure based drug development against membrane protein drug targets with a broad portfolio of innovative technolgogies, drug targets and chemical products. Pcovery apply biotechnology to improve the way people live. Pcovery creates and commercializes new drugs to treat various human and agricultural diseases.

Pluvia

Project Pluvia, based at the University of Bergen, is focused on developing small molecule chaperones for the treatment of rare genetic diseases such as Phenylketonuria.

PregMalVac

PregMalVac is a project to develop a vaccine against placental malaria, which is a significant cause of low birth weight and stillbirth in certain parts of Africa and Asia. The vaccine strategy is to induce antibodies that block the binding of malaria-infected red blood cells to the placenta.

ProRec

Prorec AB is founded by Professor Gunnar Norstedt of the Karolinska Institute and is investigating a new treatment for prolactinomas, an adenoma of the pituitary gland.

Simplexia

Simplexia is developing a novel vaccine against genital herpes caused by herpes simplex virus type 2 (HSV-2). The research behind Simplexia is based at the Sahlgrenska Academy at the University of Gothenburg.